
Phase 3 NEJM data show oveporexton improves wakefulness, reduces cataplexy, and boosts quality of life in narcolepsy type 1, with manageable adverse effects.
Finding and treating the underlying cause of sleep disturbance is critical to effective management. Here are a few medical conditions that may trigger key disrupting symptoms.

